Altshuler Shaham Ltd Sells 29 Shares of Eli Lilly and Company (NYSE:LLY)

Altshuler Shaham Ltd trimmed its position in Eli Lilly and Company (NYSE:LLY) by 0.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,319 shares of the company’s stock after selling 29 shares during the period. Eli Lilly and Company makes up approximately 0.6% of Altshuler Shaham Ltd’s portfolio, making the stock its 11th biggest position. Altshuler Shaham Ltd’s holdings in Eli Lilly and Company were worth $11,261,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in LLY. Lipe & Dalton bought a new position in shares of Eli Lilly and Company during the 4th quarter worth $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $27,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company during the 3rd quarter valued at about $36,000. Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the third quarter valued at about $40,000. Finally, O Brien Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LLY. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Bank of America lifted their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Finally, Truist Financial lifted their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Stock Down 0.4 %

Shares of NYSE:LLY traded down $3.45 during trading on Thursday, reaching $771.55. 2,169,264 shares of the stock traded hands, compared to its average volume of 3,068,803. The stock has a market cap of $733.28 billion, a P/E ratio of 113.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a 50-day moving average of $761.56 and a two-hundred day moving average of $675.58. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the business posted $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.